Approval · Notice of Compliance 15428 · 2014
NAT-RIZATRIPTAN: Notice of Compliance 15428
Issued March 19, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15428
- Date
- March 19, 2014
- Company
- Natco Pharma (Canada) IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between two companies
- Therapeutic class
- 5-ht1 receptor agonist, migraine therapy
- Canadian reference product
- MAXALT
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NAT-RIZATRIPTAN | 02421569 | Approved |
| NAT-RIZATRIPTAN | 02421577 | Approved |
Medicinal ingredients
- RIZATRIPTAN BENZOATE 5 MG per TAB
- RIZATRIPTAN BENZOATE 10 MG per TAB